Medine.co.uk

Draft Community Herbal Monograph On Oenothera Biennis L.; Oenothera Lamarckiana L., Oleum

o

EUROPEAN MEDICINES AGENCY

SCIENCE MEDICINES HEALTH

31 March 2011

EMA/HMPC/277792/2009

Committee on Herbal Medicinal Products (HMPC)

Community herbal monograph on Oenothera biennis L.; Oenothera lamarckiana L., oleum

Draft

Herbal medicinal products; HMPC; Community herbal monographs; traditional use Oenothera biennis L.; Oenothera lamarckiana L., oleum; evening primrose oil


BG (balgarski): nynama, Macno CS (cestina): pupalkovy olej DA (dansk): Kæmpenatlysolie DE (Deutsch): Nachtkerzensamenöl EL (ellinika): Oivo0gpaç eÀaio EN (English): evening primrose oil ES (espanol): Onagra, aceite de ET (eesti keel): kaheaastase kuningakepi öli FI (suomi):

FR (français): Onagre (huile d')

HU (magyar): Ligetszépe-olaj

IT (italiano): Enotera olio_


LT (lietuviq kalba):

LV (latviesu valoda): DivgadTgäs naktssveces ejja

MT (malti): Zejt tal-Oenotheria

NL (nederlands): Teunisbloemolie

PL (polski): Olej wiesiolkowy

PT (portugués): Óleo de onagra

RO (romana): ulei de lumini^a nop^ii

SK (slovencina): Pupalkovy olej

SL (slovenscina): olje dvoletnega svetlina

SV (svenska): Passionsblomma

IS (íslenska):

NO (norsk): Pasjonsblomst


Discussion in Working Party on Community monographs and Community list (MLWP)

March 2011

Adoption by Committee on Herbal Medicinal Products (HMPC) for release for consultation

31 March 2011

End of consultation (deadline for comments). Comments should be provided using this template to hmpc.secretariat@ema.europa.eu

15 August 2011

Rediscussion in Working Party on Community monographs and Community list (MLWP)

Adoption by Committee on Herbal Medicinal Products (HMPC)

Keywords

An agency of the European Union


7 Westferry Circus • Canary Wharf • London E14 4HB • United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7051 E-mail info@ema.europa.eu Website www.ema.europa.eu

© European Medicines Agency, 2011. Reproduction is authorised provided the source is acknowledged.

Community herbal monograph on Oenothera biennis L.; Oenothera lamarckiana L., oleum

1. Name of the medicinal product

To be specified for the individual finished product.

2. Qualitative and quantitative composition1,2

Well-established use

Traditional use

With regard to the marketing authorisation application of Article 10(a) of Directive 2001/83/EC as amended

Oenothera biennis L.; Oenothera lamarckiana L., oleum (evening primrose oil)

i) Herbal substance

Not applicable.

ii) Herbal preparations

Fatty oil obtained from seeds of Oenothera biennis L. or Oenothera lamarckiana L. by extraction and/or expression.

3. Pharmaceutical form

Well-established use

Traditional use

Herbal preparation in solid dosage forms for oral use.

The pharmaceutical form should be described by the European Pharmacopoeia full standard term.

1    The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance.

2    The material complies with the Ph. Eur. monograph (ref.: 01/2010:2104)._

4. Clinical particulars

4.1. Therapeutic indications

Well-established use

Traditional use

Traditional herbal medicinal product for the symptomatic relief of itching in acute and chronic dry skin conditions.

4.2. Posology and method of administration

Well-established use

Traditional use

Posology

Adolescents, adults and elderly:

Single dose: 2 g Daily dose: 4-6 g

The use in children under 12 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').

Duration of use

If the symptoms persist longer than 8 weeks during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.

Method of administration

Oral use.

4.3. Contraindications

Well-established use

Traditional use

Hypersensitivity to the active substance.

4.4. Special warnings and precautions for use

Well-established use

Traditional use

The use in children under 12 years of age has not been established due to lack of adequate data.

4.5. Interactions with other medicinal products and other forms of interaction

Well-established use

Traditional use

None reported.

4.6. Fertility, pregnancy and lactation

Well-established use

Traditional use

Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended.

4.7. Effects on ability to drive and use machines

Well-established use

Traditional use

No studies on the effect on the ability to drive and use machines have been performed.

4.8. Undesirable effects

Well-established use

Traditional use

Gastrointestinal effects, indigestion, nausea, softening of stool, rise in temperature, hypersensitive reactions like exanthema and headache have been reported. The frequency is not known.

If other adverse reactions not mentioned above occur, a doctor or a qualified health care practitioner should be consulted.

4.9. Overdose

Well-established use

Traditional use

The symptoms of overdosing are mild diarrhoea and abdominal pain. No special treatment is required.

5. Pharmacological properties

5.1. Pharmacodynamic properties

Well-established use

Traditional use

Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

5.2. Pharmacokinetic properties

Well-established use

Traditional use

Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

5.3. Preclinical safety data

Well-established use

Traditional use

Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended, unless necessary for the safe use of the product.

Adequate tests on reproductive toxicity, genotoxicity and carcinogenicity have not been performed.

6. Pharmaceutical particulars

Well-established use

Traditional use

Not applicable.

7. Date of compilation/last revision

31 March 2011

Page 6/5

Community herbal monograph on Oenothera biennis L.; Oenothera lamarckiana L.,

oleum

EMA/HMPC/277792/2009